IMI Outputs - November 2015
•
1 like•219 views
€5 billion from the EU and European pharmaceutical industry has been committed through the Innovative Medicines Initiative (IMI) public-private partnership to support drug discovery projects. IMI has funded 68 projects through open calls for proposals and established collaborations between academia, small and medium enterprises, large pharmaceutical companies, and regulators. IMI projects have resulted in over 1,100 publications, secured relevance for regulatory guidelines, generated over 2,000 direct jobs and 13,000 indirect jobs, and led to new companies and joint ventures in the biomedical sector.
Report
Share
Report
Share
Download to read offline
Recommended
THA covid – control innovations aug 2021.pptx
As of 2021 there have been some innovations which the Disease Prevention and Health Innovation Center DPHI under department of disease control , Thailand works collaboratively with many sectors. Our major role is to facilitate the co-creation of innovation in order to fight against COVID-19. User-centered design concept has been brought in to the development process. Design thinking has been practiced among health experts and technology innovators. By facilitating these projects, we learned a lot and improve our innovation collaborating skill. We aim to be one of the best health innovation hub in Asia. These projects are parts of our work.
EuroBioForum 2013 - Day 2 | Frank Molina
EuroBioForum 2013 2nd Annual Conference
27-28 May 2013 - Hilton Munich City, Munich, Germany
http://www.eurobioforum.eu/2013
=======================================
# REGIONAL PERSPECTIVES #
EuroBioMed, France:
Private-public collaborations to boost open innovation
Dr Franck Molina
President of EDCA, Chair of diagnosis group of Eurobiomed
Director of Sysdiag
=======================================
http://www.eurobioforum.eu
Data4 impact group discussions
Day 2: Open Science and Big Data in support of measuring R&I Indicators. Group discussion on the results of Data4Impact.
https://www.openaire.eu/research-policy-monitoring-in-the-era-of-open-science-and-big-data-the-what-indicators-and-the-how-infrastructures
20190528_Data4Impact_Open Science and Big data in support of measuring R&I In...
Presented by Vilius Stanciauskas, Rainer Frietsch, Alexander Feidenheimer, Haris Papageorgiou, Ioanna Grypari, Iason Demiros and Gustaf Nelhans
during the OpenAIRE workshop "Research policy monitoring in the era of Open Science and Big Data" taking place in Ghent, Belgium on May 27th and 28th 2019
Day 2: Open Science and Big Data in support of measuring R&I Indicators
https://www.openaire.eu/research-policy-monitoring-in-the-era-of-open-science-and-big-data-the-what-indicators-and-the-how-infrastructures
Medtronic
Medtronic is a medical technology company that develops life-changing technologies to treat chronic diseases. They work closely with physicians around the world and have six major business units focused on different medical conditions and therapies. Medtronic serves medical professionals by developing innovative technologies and uses a blend of Lean and Six Sigma practices in their business model. They are constantly innovating both new technologies and business processes to improve patient care and lives.
TCIOceania15 WelfareTech - Towards Industrialisation
WelfareTech is a Danish association established in 2010 to promote collaboration between businesses, hospitals, universities, and public authorities on developing intelligent solutions for healthcare and homecare services. It has 189 member organizations, including 94 companies. WelfareTech aims to address the challenges posed by Denmark's aging population through innovation in areas like telemedicine, robotics, and ICT. Its strategy for internationalization includes mapping clusters in other countries for collaboration, participating in EU innovation projects, and coordinating members' involvement in export promotion activities and international trade fairs. The goal is to help Danish companies expand into new overseas healthcare and welfare technology markets.
HealthBIO 2021_Cancer I/O Translating immuno-oncology into health actions_Jer...
This document provides a summary of an introduction to cancer immuno-oncology. It discusses utilizing the immune system to kill cancer cells and the increasing uptake of immuno-oncology drugs. It outlines the goals of the Cancer IO Office to facilitate immuno-oncology uptake through strategic foresight, societal discussion, and Finnish immuno-oncology research. The document describes the Cancer IO Office's themes of immuno-oncology in society, research, and healthcare which include developing 3D cancer culture models, utilizing real-world data to identify super responders, and analyzing immuno-oncology uptake in Finnish hospitals.
Medtronic valuation
Medtronic takes advantage of several factors in the medical device industry in which it operates. The incidence of type 1 diabetes is increasing, and active diabetics prefer insulin pumps to injections. However, the Affordable Care Act imposes an excise tax on medical device companies. Medtronic pursues a combination of low-cost and differentiation strategies. It has diversified into related businesses through acquisitions while maintaining its focus on sensing and stimulation technologies. Medtronic has strong financial performance with higher profit margins than competitors. However, the excise tax may reduce industry growth. Over the next 5 years, Medtronic is well-positioned to continue growing through cost improvements and acquiring smaller companies impacted by the tax
Recommended
THA covid – control innovations aug 2021.pptx
As of 2021 there have been some innovations which the Disease Prevention and Health Innovation Center DPHI under department of disease control , Thailand works collaboratively with many sectors. Our major role is to facilitate the co-creation of innovation in order to fight against COVID-19. User-centered design concept has been brought in to the development process. Design thinking has been practiced among health experts and technology innovators. By facilitating these projects, we learned a lot and improve our innovation collaborating skill. We aim to be one of the best health innovation hub in Asia. These projects are parts of our work.
EuroBioForum 2013 - Day 2 | Frank Molina
EuroBioForum 2013 2nd Annual Conference
27-28 May 2013 - Hilton Munich City, Munich, Germany
http://www.eurobioforum.eu/2013
=======================================
# REGIONAL PERSPECTIVES #
EuroBioMed, France:
Private-public collaborations to boost open innovation
Dr Franck Molina
President of EDCA, Chair of diagnosis group of Eurobiomed
Director of Sysdiag
=======================================
http://www.eurobioforum.eu
Data4 impact group discussions
Day 2: Open Science and Big Data in support of measuring R&I Indicators. Group discussion on the results of Data4Impact.
https://www.openaire.eu/research-policy-monitoring-in-the-era-of-open-science-and-big-data-the-what-indicators-and-the-how-infrastructures
20190528_Data4Impact_Open Science and Big data in support of measuring R&I In...
Presented by Vilius Stanciauskas, Rainer Frietsch, Alexander Feidenheimer, Haris Papageorgiou, Ioanna Grypari, Iason Demiros and Gustaf Nelhans
during the OpenAIRE workshop "Research policy monitoring in the era of Open Science and Big Data" taking place in Ghent, Belgium on May 27th and 28th 2019
Day 2: Open Science and Big Data in support of measuring R&I Indicators
https://www.openaire.eu/research-policy-monitoring-in-the-era-of-open-science-and-big-data-the-what-indicators-and-the-how-infrastructures
Medtronic
Medtronic is a medical technology company that develops life-changing technologies to treat chronic diseases. They work closely with physicians around the world and have six major business units focused on different medical conditions and therapies. Medtronic serves medical professionals by developing innovative technologies and uses a blend of Lean and Six Sigma practices in their business model. They are constantly innovating both new technologies and business processes to improve patient care and lives.
TCIOceania15 WelfareTech - Towards Industrialisation
WelfareTech is a Danish association established in 2010 to promote collaboration between businesses, hospitals, universities, and public authorities on developing intelligent solutions for healthcare and homecare services. It has 189 member organizations, including 94 companies. WelfareTech aims to address the challenges posed by Denmark's aging population through innovation in areas like telemedicine, robotics, and ICT. Its strategy for internationalization includes mapping clusters in other countries for collaboration, participating in EU innovation projects, and coordinating members' involvement in export promotion activities and international trade fairs. The goal is to help Danish companies expand into new overseas healthcare and welfare technology markets.
HealthBIO 2021_Cancer I/O Translating immuno-oncology into health actions_Jer...
This document provides a summary of an introduction to cancer immuno-oncology. It discusses utilizing the immune system to kill cancer cells and the increasing uptake of immuno-oncology drugs. It outlines the goals of the Cancer IO Office to facilitate immuno-oncology uptake through strategic foresight, societal discussion, and Finnish immuno-oncology research. The document describes the Cancer IO Office's themes of immuno-oncology in society, research, and healthcare which include developing 3D cancer culture models, utilizing real-world data to identify super responders, and analyzing immuno-oncology uptake in Finnish hospitals.
Medtronic valuation
Medtronic takes advantage of several factors in the medical device industry in which it operates. The incidence of type 1 diabetes is increasing, and active diabetics prefer insulin pumps to injections. However, the Affordable Care Act imposes an excise tax on medical device companies. Medtronic pursues a combination of low-cost and differentiation strategies. It has diversified into related businesses through acquisitions while maintaining its focus on sensing and stimulation technologies. Medtronic has strong financial performance with higher profit margins than competitors. However, the excise tax may reduce industry growth. Over the next 5 years, Medtronic is well-positioned to continue growing through cost improvements and acquiring smaller companies impacted by the tax
A Trust-Centric Healthcare Journey | Full Presentation of PharmaLedger's 1st ...
In this #1 Open Webinar | A trust-centric healthcare journey presentation, you will find:
An introduction to the PharmaLedger project presented by Lynn Wang (Johnson & Johnson)
Topic 1 | Clinical Supply Traceability presented by Francesco Spoto (Novartis) and Chad Sklodosky (Pfizer)
Topic 2 | Finished Goods Traceability presented by Dr Jan Wortmann (Bayer) and Bernhard Salb (Roche)
Topic 3 | ePI – Electronic Product Information presented by Patrick Maher (Novartis) and Ken Thursby (MSD)
Topic 4 | Anti-Counterfeiting presented by Daniel Fritz (Novartis) and Alberto Lòpez (Imprensa Nacional Casa da Moeda)
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 853992. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
Disclaimer: Any information on this presentation solely reflects the author’s view and neither IMI nor the European Union or EFPIA are responsible for any use that may be made of the information contained herein.
Innovate UK Future Worlds Event - Living World – Mark Kelly
The Knowledge Transfer Network (KTN) is the UK's innovation network that brings together businesses, academics, entrepreneurs and funders to develop new products, processes and services. The KTN helps businesses grow the economy and improve lives by maximizing the value of innovative ideas, research and creativity. It focuses on priority areas like health technologies, manufacturing, and bioinformatics to diagnose, treat and manage diseases while improving quality of life. The KTN provides support for businesses through funding connections, access to expertise in centers of excellence, assistance developing supply chains, and help navigating complex innovation issues.
Medtronic case study - hybris global eCommerce platform
SapientNitro partnered with hybris to deliver a global e-commerce solution for Medtronic that supports multiple brands, products, services, and scenarios across countries. The solution provides an omni-channel view of orders, shipment tracking, and self-service access to activities like re-ordering. It has standardized Medtronic's customer experience, reduced costs by eliminating manual processes, and given insights from digital analytics.
HCF 2018 Panel 2: Martin Kayser
PANEL 2: Endocrine disruptors as a challenge for risk communication
Presentation: Martin Kayser, Senior Vice President of Product Safety, BASF, Germany
HealthBIO 2021_PerkinElmer, leading with innovation - from COVID success into...
This document provides an overview of PerkinElmer, a company focused on diagnostics, life sciences, food, and applied markets. It discusses their mission of innovating for a healthier world, with over 80 years of innovations including a COVID-19 PCR kit launched in 2020. The company's diagnostics segment focuses on reproductive health, immunoassays, and applied genomics. PerkinElmer has global capabilities across molecular diagnostics, imaging, automation, and more. It is pursuing growth in areas like single-cell analysis, therapeutics, digital solutions, and decentralized testing. The company's strategy focuses on detection, decentralization, and digitization to drive profitable growth.
HealthBIO 2021,_The InFlames Flagship_Timo Veromaa
The document provides an overview of the InFLAMES Research Flagship program at the University of Turku in Finland. Some key points:
- InFLAMES brings together over 300 researchers from the University of Turku and Åbo Akademi University focused on immunology research.
- The program aims to make breakthroughs in drug development, diagnostics, and precision immune medicine through discovery, testing, and utilization of novel immunological findings.
- It provides researchers access to high-quality open access research infrastructure facilities like the Turku Bioscience Centre, Turku PET Centre, and Auria Biobank to support both academic and industry collaborations.
- Measuring impact, InFLAMES
mhealth - The role of Technology
The document discusses mHealth and the role of technology in healthcare. It summarizes the research at WIT including over 400 research staff and €20 million in research expenditures annually. TSSG is highlighted as a leading software R&D center with expertise in mobile and communications services. TSSG works to meet expectations for mHealth such as making healthcare more accessible and personalized while addressing barriers like interoperability, security, and clinical evidence. Example projects highlighted include cloud-based connected devices, point-of-care apps, augmented reality for surgery, and mobile imaging solutions.
HealthBIO 2020_Tero Piispanen_Turku Science Park
- 12 new biotech companies were created in Finland between June 2019 and October 2020, the smallest number in years, due to the COVID-19 pandemic.
- Total Finnish health tech export was €2.4 billion in 2019, with China as the largest export market thanks to strong demand for diagnostic equipment.
- Several Finnish biotech companies had successful clinical trials, funding rounds, partnerships and FDA/EMA approvals in areas such as oncology, neurology, rare diseases and COVID-19 vaccines.
Medtronic - A brief company analysis
Medtronic is a global medical device company headquartered in Ireland with over 90,000 employees worldwide. It develops, manufactures and markets medical equipment and therapies for over 70 conditions. Key areas include cardiovascular, orthopedics, diabetes and more. While Medtronic dominates many markets, it faces challenges around product reliability, regulatory compliance, costs and competition. The document analyzes Medtronic's financials, markets, competitors and recommends prioritizing investments in emerging markets and developing products for mid-tier segments in those regions.
HealthBIO 2021_Orion’s new strategy and industry trends seen from a midsize p...
This presentation provides an overview of Orion's new strategy from a midsize pharmaceutical perspective. It discusses Orion's business segments and key financial metrics. It then summarizes major pharmaceutical industry trends, including aging populations, advances in technology, and increased regulation. Finally, it outlines Orion's strategic growth target of €1.5 billion in net sales by 2025 and focus areas to achieve this, such as delivering its late-stage portfolio, building its pipeline, maximizing the value of existing assets, and exploring new partnerships and technologies.
Health Valley Event Presentatie Rob ten Hoedt
1. Rob ten Hoedt, President of Medtronic Europe, gave a presentation on the medical technology industry and Medtronic's role in innovation in Europe.
2. Key trends in European healthcare include aging populations, rising costs, and a focus on prevention and chronic disease management outside hospitals.
3. Medtronic is developing innovative solutions like implantable devices, biologics, and wireless technologies to treat conditions like heart disease, diabetes, and neurological disorders.
Clinical Trial eRecruitment | Topic #1 of PharmaLedger's 2nd Open Webinar
In this Clinical Trial eRecruitment Use Case presentation, you will find:
An introduction to Clinical Trial eRecruitment use case presented by: Despina Daliani (Onorach) and Ken Nessel (Pfizer)
The current Clinical Trial Recruitment process
Pain points of the Clinical Trial eRecruitment
PharmaLedger’s Clinical Trial eRecruitment solution for the future state
Value added by PharmaLedger per actor involved
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 853992. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
Disclaimer: Any information on this presentation solely reflects the author’s view and neither IMI nor the European Union or EFPIA are responsible for any use that may be made of the information contained herein.
HealthBIO 2021_Finnish biotech year 2021_Tero Piispanen
Finnish biotech year 2020-2021 saw the creation of 12 new companies in areas like drug development, diagnostics, and medtech. The health tech industry in Finland continues to grow with record exports in 2020. Several Finnish companies had successes including clinical trial progress, partnerships, and facility expansions. However, venture capital investment in Finnish life sciences remains low compared to Europe, with Finnish companies often only receiving seed funding.
A Trust-Centric Healthcare Journey Part II | Full Presentation of PharmaLedge...
In this presentation, you will find:
An introduction to the PharmaLedger project presented by Maria Eugenia (Xenia) Beltran | Project Coordinator / DRA and Use Case co-lead (Universidad Politécnica de Madrid)
Topic 1 | Clinical Trial eRecruitment | Despina Daliani (Onorach) and Ken Nessel (Pfizer)
Topic 2 | Clinical Trial eConsent | Hernando C. Giraldo (Boehringer Ingelheim) and Despina Daliani (Onorach)
Topic 3 | Health Data IoT Medical Device | Disa Lee Choun (UCB) and Francesca Rocchi (Bambino Gesù Children Hospital)
Topic 4 | Health Data Personalised Medicine | Beatriz Merino (Universidad Politécnica de Madrid) and Christos Kontogiorgis (Democritus University of Thrace)
You can also learn more about our #2 Open Webinar on Clinical Trials & Health Data by rewatching our video recording including the Q&A by clicking on the button below:
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 853992. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
Disclaimer: Any information on this presentation solely reflects the author’s view and neither IMI nor the European Union or EFPIA are responsible for any use that may be made of the information contained herein.
Health tech & endless opportunities
This document discusses concepts related to the global health-tech industry. It provides an overview of key topics including the healthcare and life sciences industry in 2020, technologies and startups disrupting the status quo, a focus on the medical device industry globally and in India, and a concept note on syringe counterfeiting. The document also analyzes funding trends in 2020, highlights major disruptors like telemedicine, and provides snapshots on medical devices and new anti-counterfeiting technologies.
What Can We Learn from Open Source and Open Standards
This document discusses the benefits of open source and open standards models compared to traditional pharmaceutical models. It notes that open source and open standards approaches enable very broad global collaboration, voluntary participation and sharing of intellectual property. This results in thousands of new efforts launched each year, ubiquitous adoption, low costs and proliferation of platforms for innovation. The key to their success is that participants trust the system and believe in the rewards. Some of the rewards include building ecosystems with network effects, level playing fields that ensure equal opportunities, and intellectual property rules that benefit all participants. The lessons are that open models work best for certain domains, and their design must provide a valuable proposition to all key stakeholders to default to success.
HCF 2018 Panel 2: Barbara Demeneix
The document discusses endocrine disrupting chemicals (EDCs) and their effects:
- EDCs can have low dose effects and no threshold of exposure, and exposure during fetal and child development windows can cause long-term health impacts. On average, every baby is exposed to over 100 potential EDCs.
- The speaker's research has focused on thyroid EDCs and their links to brain development, having published numerous papers and books on the topic. Their work helped establish the Watchfrog organization in 2005.
- Studies show that EDCs found in maternal blood are also present in amniotic fluid, where they can alter thyroid hormone signaling, brain gene expression, and behavior in animal models.
HCF 2018 Panel 2: Axel Singhofen
PANEL 2: Endocrine disruptors as a challenge for risk communication
Presentation: Axel Singhofen, Adviser on Health and Environment Policy, Greens/EFA in the European Parliament
IoT Medical Devices | Topic #3 of PharmaLedger's 2nd Open Webinar
In this IoT Medical Device Use Case presentation, you will find:
An introduction to IoT Medical Device use case presented by : Disa Lee Choun (UCB) and Francesca Rocchi (Bambino Gesù Children Hospital)
The current state and challenges of data collection from medical devices
The advantages of IoT in Clinical Trials
PharmaLedger’s blockchain solution for the future state
Value added by PharmaLedger per actor involved
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 853992. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
Disclaimer: Any information on this presentation solely reflects the author’s view and neither IMI nor the European Union or EFPIA are responsible for any use that may be made of the information contained herein.
Medteq Industrial R&D and Innovation Consortium
MEDTEQ is an industrial R&D program that supports collaboration between industry, public research institutions, and healthcare providers to reduce risks and facilitate knowledge transfer. The objectives are to intersect industrial and public research and support strategic alliances. MEDTEQ consortia operate in various medical technology sectors in Quebec. Key benefits include collaboration across the technology spectrum, between large multinationals and small and medium enterprises, and development of highly qualified personnel. Participating industry members provide mandatory funding towards innovation projects, while MEDTEQ and other public agencies provide additional funding. This leverages resources to shorten product development cycles and engage healthcare institutions as partners to build products for international markets and establish a medical technology community of practice.
PLANEACIÓN DEL CICLO UNO DEL PROCESO INVESTIGATIVO
Este documento describe las tres fases del primer ciclo de un plan de acción pedagógico: planificación, observación y reflexión. En la fase de observación, se llevaron a cabo tres actividades con los estudiantes: una actividad con rollos, una carrera de obstáculos y una coreografía cantada. En la fase de reflexión, se analizaron los resultados de pruebas sobre motricidad fina, gruesa y ubicación espacial de los estudiantes.
Cancer de cuello uterino
Este documento describe el cáncer de cérvix o cuello uterino. Explica que se origina en el cérvix y se transmite principalmente a través del virus del papiloma humano. Los síntomas no suelen aparecer hasta etapas avanzadas y la detección temprana a través de pruebas de Papanicolaou es clave para prevenirlo. Los tratamientos incluyen cirugía, radioterapia y quimioterapia dependiendo del estadio, con el objetivo de extirpar el tejido canceroso. La vacunación contra el
More Related Content
What's hot
A Trust-Centric Healthcare Journey | Full Presentation of PharmaLedger's 1st ...
In this #1 Open Webinar | A trust-centric healthcare journey presentation, you will find:
An introduction to the PharmaLedger project presented by Lynn Wang (Johnson & Johnson)
Topic 1 | Clinical Supply Traceability presented by Francesco Spoto (Novartis) and Chad Sklodosky (Pfizer)
Topic 2 | Finished Goods Traceability presented by Dr Jan Wortmann (Bayer) and Bernhard Salb (Roche)
Topic 3 | ePI – Electronic Product Information presented by Patrick Maher (Novartis) and Ken Thursby (MSD)
Topic 4 | Anti-Counterfeiting presented by Daniel Fritz (Novartis) and Alberto Lòpez (Imprensa Nacional Casa da Moeda)
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 853992. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
Disclaimer: Any information on this presentation solely reflects the author’s view and neither IMI nor the European Union or EFPIA are responsible for any use that may be made of the information contained herein.
Innovate UK Future Worlds Event - Living World – Mark Kelly
The Knowledge Transfer Network (KTN) is the UK's innovation network that brings together businesses, academics, entrepreneurs and funders to develop new products, processes and services. The KTN helps businesses grow the economy and improve lives by maximizing the value of innovative ideas, research and creativity. It focuses on priority areas like health technologies, manufacturing, and bioinformatics to diagnose, treat and manage diseases while improving quality of life. The KTN provides support for businesses through funding connections, access to expertise in centers of excellence, assistance developing supply chains, and help navigating complex innovation issues.
Medtronic case study - hybris global eCommerce platform
SapientNitro partnered with hybris to deliver a global e-commerce solution for Medtronic that supports multiple brands, products, services, and scenarios across countries. The solution provides an omni-channel view of orders, shipment tracking, and self-service access to activities like re-ordering. It has standardized Medtronic's customer experience, reduced costs by eliminating manual processes, and given insights from digital analytics.
HCF 2018 Panel 2: Martin Kayser
PANEL 2: Endocrine disruptors as a challenge for risk communication
Presentation: Martin Kayser, Senior Vice President of Product Safety, BASF, Germany
HealthBIO 2021_PerkinElmer, leading with innovation - from COVID success into...
This document provides an overview of PerkinElmer, a company focused on diagnostics, life sciences, food, and applied markets. It discusses their mission of innovating for a healthier world, with over 80 years of innovations including a COVID-19 PCR kit launched in 2020. The company's diagnostics segment focuses on reproductive health, immunoassays, and applied genomics. PerkinElmer has global capabilities across molecular diagnostics, imaging, automation, and more. It is pursuing growth in areas like single-cell analysis, therapeutics, digital solutions, and decentralized testing. The company's strategy focuses on detection, decentralization, and digitization to drive profitable growth.
HealthBIO 2021,_The InFlames Flagship_Timo Veromaa
The document provides an overview of the InFLAMES Research Flagship program at the University of Turku in Finland. Some key points:
- InFLAMES brings together over 300 researchers from the University of Turku and Åbo Akademi University focused on immunology research.
- The program aims to make breakthroughs in drug development, diagnostics, and precision immune medicine through discovery, testing, and utilization of novel immunological findings.
- It provides researchers access to high-quality open access research infrastructure facilities like the Turku Bioscience Centre, Turku PET Centre, and Auria Biobank to support both academic and industry collaborations.
- Measuring impact, InFLAMES
mhealth - The role of Technology
The document discusses mHealth and the role of technology in healthcare. It summarizes the research at WIT including over 400 research staff and €20 million in research expenditures annually. TSSG is highlighted as a leading software R&D center with expertise in mobile and communications services. TSSG works to meet expectations for mHealth such as making healthcare more accessible and personalized while addressing barriers like interoperability, security, and clinical evidence. Example projects highlighted include cloud-based connected devices, point-of-care apps, augmented reality for surgery, and mobile imaging solutions.
HealthBIO 2020_Tero Piispanen_Turku Science Park
- 12 new biotech companies were created in Finland between June 2019 and October 2020, the smallest number in years, due to the COVID-19 pandemic.
- Total Finnish health tech export was €2.4 billion in 2019, with China as the largest export market thanks to strong demand for diagnostic equipment.
- Several Finnish biotech companies had successful clinical trials, funding rounds, partnerships and FDA/EMA approvals in areas such as oncology, neurology, rare diseases and COVID-19 vaccines.
Medtronic - A brief company analysis
Medtronic is a global medical device company headquartered in Ireland with over 90,000 employees worldwide. It develops, manufactures and markets medical equipment and therapies for over 70 conditions. Key areas include cardiovascular, orthopedics, diabetes and more. While Medtronic dominates many markets, it faces challenges around product reliability, regulatory compliance, costs and competition. The document analyzes Medtronic's financials, markets, competitors and recommends prioritizing investments in emerging markets and developing products for mid-tier segments in those regions.
HealthBIO 2021_Orion’s new strategy and industry trends seen from a midsize p...
This presentation provides an overview of Orion's new strategy from a midsize pharmaceutical perspective. It discusses Orion's business segments and key financial metrics. It then summarizes major pharmaceutical industry trends, including aging populations, advances in technology, and increased regulation. Finally, it outlines Orion's strategic growth target of €1.5 billion in net sales by 2025 and focus areas to achieve this, such as delivering its late-stage portfolio, building its pipeline, maximizing the value of existing assets, and exploring new partnerships and technologies.
Health Valley Event Presentatie Rob ten Hoedt
1. Rob ten Hoedt, President of Medtronic Europe, gave a presentation on the medical technology industry and Medtronic's role in innovation in Europe.
2. Key trends in European healthcare include aging populations, rising costs, and a focus on prevention and chronic disease management outside hospitals.
3. Medtronic is developing innovative solutions like implantable devices, biologics, and wireless technologies to treat conditions like heart disease, diabetes, and neurological disorders.
Clinical Trial eRecruitment | Topic #1 of PharmaLedger's 2nd Open Webinar
In this Clinical Trial eRecruitment Use Case presentation, you will find:
An introduction to Clinical Trial eRecruitment use case presented by: Despina Daliani (Onorach) and Ken Nessel (Pfizer)
The current Clinical Trial Recruitment process
Pain points of the Clinical Trial eRecruitment
PharmaLedger’s Clinical Trial eRecruitment solution for the future state
Value added by PharmaLedger per actor involved
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 853992. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
Disclaimer: Any information on this presentation solely reflects the author’s view and neither IMI nor the European Union or EFPIA are responsible for any use that may be made of the information contained herein.
HealthBIO 2021_Finnish biotech year 2021_Tero Piispanen
Finnish biotech year 2020-2021 saw the creation of 12 new companies in areas like drug development, diagnostics, and medtech. The health tech industry in Finland continues to grow with record exports in 2020. Several Finnish companies had successes including clinical trial progress, partnerships, and facility expansions. However, venture capital investment in Finnish life sciences remains low compared to Europe, with Finnish companies often only receiving seed funding.
A Trust-Centric Healthcare Journey Part II | Full Presentation of PharmaLedge...
In this presentation, you will find:
An introduction to the PharmaLedger project presented by Maria Eugenia (Xenia) Beltran | Project Coordinator / DRA and Use Case co-lead (Universidad Politécnica de Madrid)
Topic 1 | Clinical Trial eRecruitment | Despina Daliani (Onorach) and Ken Nessel (Pfizer)
Topic 2 | Clinical Trial eConsent | Hernando C. Giraldo (Boehringer Ingelheim) and Despina Daliani (Onorach)
Topic 3 | Health Data IoT Medical Device | Disa Lee Choun (UCB) and Francesca Rocchi (Bambino Gesù Children Hospital)
Topic 4 | Health Data Personalised Medicine | Beatriz Merino (Universidad Politécnica de Madrid) and Christos Kontogiorgis (Democritus University of Thrace)
You can also learn more about our #2 Open Webinar on Clinical Trials & Health Data by rewatching our video recording including the Q&A by clicking on the button below:
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 853992. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
Disclaimer: Any information on this presentation solely reflects the author’s view and neither IMI nor the European Union or EFPIA are responsible for any use that may be made of the information contained herein.
Health tech & endless opportunities
This document discusses concepts related to the global health-tech industry. It provides an overview of key topics including the healthcare and life sciences industry in 2020, technologies and startups disrupting the status quo, a focus on the medical device industry globally and in India, and a concept note on syringe counterfeiting. The document also analyzes funding trends in 2020, highlights major disruptors like telemedicine, and provides snapshots on medical devices and new anti-counterfeiting technologies.
What Can We Learn from Open Source and Open Standards
This document discusses the benefits of open source and open standards models compared to traditional pharmaceutical models. It notes that open source and open standards approaches enable very broad global collaboration, voluntary participation and sharing of intellectual property. This results in thousands of new efforts launched each year, ubiquitous adoption, low costs and proliferation of platforms for innovation. The key to their success is that participants trust the system and believe in the rewards. Some of the rewards include building ecosystems with network effects, level playing fields that ensure equal opportunities, and intellectual property rules that benefit all participants. The lessons are that open models work best for certain domains, and their design must provide a valuable proposition to all key stakeholders to default to success.
HCF 2018 Panel 2: Barbara Demeneix
The document discusses endocrine disrupting chemicals (EDCs) and their effects:
- EDCs can have low dose effects and no threshold of exposure, and exposure during fetal and child development windows can cause long-term health impacts. On average, every baby is exposed to over 100 potential EDCs.
- The speaker's research has focused on thyroid EDCs and their links to brain development, having published numerous papers and books on the topic. Their work helped establish the Watchfrog organization in 2005.
- Studies show that EDCs found in maternal blood are also present in amniotic fluid, where they can alter thyroid hormone signaling, brain gene expression, and behavior in animal models.
HCF 2018 Panel 2: Axel Singhofen
PANEL 2: Endocrine disruptors as a challenge for risk communication
Presentation: Axel Singhofen, Adviser on Health and Environment Policy, Greens/EFA in the European Parliament
IoT Medical Devices | Topic #3 of PharmaLedger's 2nd Open Webinar
In this IoT Medical Device Use Case presentation, you will find:
An introduction to IoT Medical Device use case presented by : Disa Lee Choun (UCB) and Francesca Rocchi (Bambino Gesù Children Hospital)
The current state and challenges of data collection from medical devices
The advantages of IoT in Clinical Trials
PharmaLedger’s blockchain solution for the future state
Value added by PharmaLedger per actor involved
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 853992. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
Disclaimer: Any information on this presentation solely reflects the author’s view and neither IMI nor the European Union or EFPIA are responsible for any use that may be made of the information contained herein.
Medteq Industrial R&D and Innovation Consortium
MEDTEQ is an industrial R&D program that supports collaboration between industry, public research institutions, and healthcare providers to reduce risks and facilitate knowledge transfer. The objectives are to intersect industrial and public research and support strategic alliances. MEDTEQ consortia operate in various medical technology sectors in Quebec. Key benefits include collaboration across the technology spectrum, between large multinationals and small and medium enterprises, and development of highly qualified personnel. Participating industry members provide mandatory funding towards innovation projects, while MEDTEQ and other public agencies provide additional funding. This leverages resources to shorten product development cycles and engage healthcare institutions as partners to build products for international markets and establish a medical technology community of practice.
What's hot (20)
A Trust-Centric Healthcare Journey | Full Presentation of PharmaLedger's 1st ...
A Trust-Centric Healthcare Journey | Full Presentation of PharmaLedger's 1st ...
Innovate UK Future Worlds Event - Living World – Mark Kelly
Innovate UK Future Worlds Event - Living World – Mark Kelly
Medtronic case study - hybris global eCommerce platform
Medtronic case study - hybris global eCommerce platform
HealthBIO 2021_PerkinElmer, leading with innovation - from COVID success into...
HealthBIO 2021_PerkinElmer, leading with innovation - from COVID success into...
HealthBIO 2021,_The InFlames Flagship_Timo Veromaa
HealthBIO 2021,_The InFlames Flagship_Timo Veromaa
HealthBIO 2021_Orion’s new strategy and industry trends seen from a midsize p...
HealthBIO 2021_Orion’s new strategy and industry trends seen from a midsize p...
Clinical Trial eRecruitment | Topic #1 of PharmaLedger's 2nd Open Webinar
Clinical Trial eRecruitment | Topic #1 of PharmaLedger's 2nd Open Webinar
HealthBIO 2021_Finnish biotech year 2021_Tero Piispanen
HealthBIO 2021_Finnish biotech year 2021_Tero Piispanen
A Trust-Centric Healthcare Journey Part II | Full Presentation of PharmaLedge...
A Trust-Centric Healthcare Journey Part II | Full Presentation of PharmaLedge...
What Can We Learn from Open Source and Open Standards
What Can We Learn from Open Source and Open Standards
IoT Medical Devices | Topic #3 of PharmaLedger's 2nd Open Webinar
IoT Medical Devices | Topic #3 of PharmaLedger's 2nd Open Webinar
Viewers also liked
PLANEACIÓN DEL CICLO UNO DEL PROCESO INVESTIGATIVO
Este documento describe las tres fases del primer ciclo de un plan de acción pedagógico: planificación, observación y reflexión. En la fase de observación, se llevaron a cabo tres actividades con los estudiantes: una actividad con rollos, una carrera de obstáculos y una coreografía cantada. En la fase de reflexión, se analizaron los resultados de pruebas sobre motricidad fina, gruesa y ubicación espacial de los estudiantes.
Cancer de cuello uterino
Este documento describe el cáncer de cérvix o cuello uterino. Explica que se origina en el cérvix y se transmite principalmente a través del virus del papiloma humano. Los síntomas no suelen aparecer hasta etapas avanzadas y la detección temprana a través de pruebas de Papanicolaou es clave para prevenirlo. Los tratamientos incluyen cirugía, radioterapia y quimioterapia dependiendo del estadio, con el objetivo de extirpar el tejido canceroso. La vacunación contra el
LED Bulbs Presentation
LET US INTRODUCE YOU TO OUR VAST ARRAY OF
LED BULBS: A19, B11, BR20, BR30, BR40, PAR20, PAR30, PAR38, MR16
AngelicaRosario_CV082016
Gec is a recent graduate seeking a career in human resources. She has a Bachelor's degree in Human Resource Management from San Beda College. She has experience working in administrative and HR specialist roles at Ros-Alva Marketing Corporation and Coca-Cola. Gec is proficient in Microsoft Office, communication, and time management and is looking for opportunities in organizational development, training, recruitment, and employee communications.
Cuidando el-aparato-digestivo
Este documento habla sobre la gastritis, una enfermedad común del aparato digestivo. Explica que la gastritis es la inflamación de la mucosa del estómago y que la bacteria Helicobacter pylori es la principal causa. También menciona factores como el consumo de antiinflamatorios, alcohol y malos hábitos alimenticios que pueden causar gastritis. Finalmente, da consejos para prevenir la gastritis como lavarse las manos, beber agua, comer a horas fijas y moderar el consumo de al
RESUME YOGENDRA.
Yogendra Kumar Yogi is seeking a challenging position in hospitality management with 13 years of experience as an executive housekeeper. He currently works at Hotel Ranbanka Palace Jodhpur, where he supervises staff, controls costs and budgets, and handles all housekeeping procedures. Yogi has a diploma in hotel management and graduation from Maharishi Dayanand Sarasvati University. He has received certificates of appreciation from top hotels for his performance and aims to further his career with his communication skills and problem-solving abilities.
Lemken smaragd 9/400 parts catalog
http://partcatalogs.net - agri parts catalogs, truck parts catalogs and more.
Ever lighting catalog 2015 NEW
Ever Lighting Industrial Co., Ltd. is one of China's manufacturers and exporters of outdoor/indoor lighting fixtures and lighting sources. Our main products are die-cast aluminum lighting fixtures, such as floodlights, garden lights, bulkheads, down lights, etc. All of our products are mainly exported to Europe, South America, South Africa, the Middle East and Southeast Asia. Wish we have the honor to set good business relationship with you.
Eee mcq all chap. ( Surendr)
The document discusses the benefits of exercise for mental health. Regular physical activity can help reduce anxiety and depression and improve mood and cognitive function. Exercise causes chemical changes in the brain that may help protect against mental illness and improve symptoms for those who already suffer from conditions like anxiety and depression.
About me
This document introduces Amale Cherkaoui, who was born in Morocco in 1995 and currently lives in Lleida, Spain. She finished secondary education in 2012 and obtained her bachelor's degree in 2014. She is currently studying English philology at the University of Lleida. Her professional experience includes working in a fruit warehouse and currently as a waitress. She enjoys writing, drawing, volleyball, running and swimming in her free time. The goal of her blog is to help English learners by providing fun and effective learning advice. Her dream is to become an English teacher.
Isis sin velo V. 3
Este largo documento describe la gran diversidad de creencias religiosas en los Estados Unidos, incluidas las 15 sectas cristianas mayores, los judíos, religiones orientales y otros grupos más pequeños como los mormones. También discute las divisiones entre los materialistas, espiritistas y clérigos, y cómo las diferentes iglesias cristianas difieren en sus creencias sobre Dios, Jesús y la inmortalidad del alma. Finalmente, analiza la oposición de la Iglesia Católica y el clero protestante hacia el espiritismo moderno
Paragraph types
There are four main types of paragraphs: narrative, expository, descriptive, and persuasive. Narrative paragraphs tell a story through events in chronological order. Expository paragraphs provide information to inform or explain by using facts and citations. Descriptive paragraphs use vivid details and imagery to describe a scene or object. Persuasive paragraphs aim to convince the reader of a viewpoint by presenting a clear argument and calling the reader to action.
Cabala conocimiento completo
Este documento presenta un resumen de 3 oraciones o menos del libro "La Cabala: El Conocimiento Completo" de Santiago Aranegui.
El libro explora la Cabala como una antigua doctrina secreta que revela el conocimiento total sobre el origen del hombre, su razón de existir y su destino. A través de la Cabala, el sentido de la vida cobra significado al descubrirse el lugar del hombre en el gran plan cósmico. El libro busca despertar el conocimiento dormido en el interior del hombre sobre su naturaleza divina a través de
A study on investors’ awareness level on mutual fund & promotion of sip plan
Here are the key tables from the document:
Table 2.1 - Shows total net asset in U.S. Dollars for mutual funds globally from 1980 to 2018.
Table 2.4 - Provides the latest AUM (assets under management) and ranking for top mutual funds in India.
Table 3.1 - Provides a snapshot of different types of mutual fund schemes.
Table 3.2 - Outlines the tax rules for mutual fund investors in India.
Table 3.3 - Defines the statistical measure R-squared.
Table 3.4 - Shows the returns that can be generated through SIP (Systematic Investment Plan) over different time periods.
Table 3.5 - Describ
Gonzalez wippler migene el libro completo de magia hechizos y ceremonias
Este documento presenta un resumen de la evolución de la magia a través de la historia humana. Comienza describiendo evidencia de prácticas mágicas y rituales funerarios en el hombre de Neanderthal. Luego describe cómo el hombre de Cro-Magnon decoraba a sus muertos y los enterraba con objetos, así como también realizaba pinturas mágicas en cavernas para asegurar el éxito en la caza. Finalmente, explica que las cuevas fueron usadas como lugares sagrados y de enterramiento en muchas antiguas culturas deb
Viewers also liked (17)
PLANEACIÓN DEL CICLO UNO DEL PROCESO INVESTIGATIVO
PLANEACIÓN DEL CICLO UNO DEL PROCESO INVESTIGATIVO
Hubunganetnik islamhubunganetnik-100822014054-phpapp02
Hubunganetnik islamhubunganetnik-100822014054-phpapp02
A study on investors’ awareness level on mutual fund & promotion of sip plan
A study on investors’ awareness level on mutual fund & promotion of sip plan
Gonzalez wippler migene el libro completo de magia hechizos y ceremonias
Gonzalez wippler migene el libro completo de magia hechizos y ceremonias
Similar to IMI Outputs - November 2015
Pistoia Alliance European Conference 2015 - Ann Martin / IMI
Slides from a presentation given at the Pistoia Alliance European Conference 2015, in Zurich, Switzerland.
Finland innovation and china
This document describes the Medical Device Gateway (MDG) program, a Chinese-Finnish network aimed at commercializing medical device technologies. The program seeks to bring Chinese medical device innovations to European markets through Finnish companies, and to open Chinese markets to Finnish medical ventures. It identifies opportunities in the large and growing Chinese IVD market and regulatory changes making it more accessible. The document outlines the program's operations of establishing strategic partnerships between Finnish and Chinese organizations to more quickly develop and place new products on global markets.
IMI Graham Hughes
The Innovative Medicines Initiative (IMI) is a public-private partnership between the European Union and the pharmaceutical industry that aims to boost pharmaceutical innovation in Europe. IMI supports pre-competitive research to accelerate the development of safer and more effective medicines through collaboration between stakeholders like industry, academia, patient organizations, and regulators. IMI is funded jointly by the EU and EFPIA members, with EU funds exclusively supporting public and nonprofit organizations and SMEs.
Boosting drug development through public private partnerships (Laverty OECD P...
Presentation from the conference Science diplomacy in action Governance for international science co-operation: the example of Health Research 11-12 February, 2013, arranged by the French and British embassies as a follow up to the OECD STIG project, see http://beyondstig.oecd.org
A Journey from Patient Needs to Health Solutions
Copyright - Jackie Oldham, Manchester Integrated Medicine and Innovative Technologies, University of Manchester, 2011
The Changing Pharma R&D Model, GDDIS Leaders Summit Ted Torphy CSO, Head, Ex...
The Changing Pharma R&D Model, GDDIS Leaders Summit Ted Torphy CSO, Head, External Innovation Research Excellence, Advance Technologies Janssen R&D
A Johnson & Johnson Pharmaceutical Company
Previous Position
www.gbx.uk.com
www.gddis.com
www.gddif.com
www.wddis.com
Earma Annual Conference 23 june 2011 - Magali Poinot (part 1)
The Innovative Medicines Initiative (IMI) is a public-private partnership between the European Union and the pharmaceutical industry that aims to boost pharmaceutical innovation in Europe. IMI supports precompetitive research through large collaborative projects involving multiple stakeholders. The initial IMI projects focused on developing biomarkers and tools to help develop more targeted treatments, characterizing diseases like asthma to enable personalized medicine, and establishing databases and models to better predict drug toxicity and safety. The current IMI research agenda is being revised to broaden its focus beyond early drug development and make the entire EU drug development process more efficient.
Infection Surveillance Solutions Market PPT: Growth, Outlook, Demand, Keyplay...
The global infection surveillance solutions market size reached US$ 652.6 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 1,314.8 Million by 2032, exhibiting a growth rate (CAGR) of 7.65% during 2024-2032.
More Info:- https://www.imarcgroup.com/infection-surveillance-solutions-market
Graham Hughes - Beta Technology - FP 7 Call Presentation
The document provides an overview of the FP7 2012 Health Call, including:
- FP7 is the EU's 7th Framework Programme for research and development, investing €53 billion from 2007-2013. The Health Theme funds collaborative research projects.
- The 2012 call focuses on innovation, with topics targeting active and healthy aging, medical technologies, clinical trials, and other priority areas.
- There are several SME-focused topics, including a new pilot SME innovation call. The call aims to mobilize resources around key challenges and achieve both short and long term outcomes.
Real World Outcomes Across the AD (Alzheimer’s disease) Spectrum (ROADS) to B...
The document describes the Real World Outcomes Across the AD Spectrum (ROADS) topic, which aims to develop recommendations on appropriate outcome measures and data sources to characterize Alzheimer's disease across its spectrum in real-world settings. The project will define patient-relevant outcomes, identify data sources, and provide guidance on modeling disease progression using existing data. This will inform a subsequent prospective data collection effort to generate real-world evidence on AD and optimize care systems. The collaboration involves industry, academic, regulatory, HTA and patient organizations to ensure the work supports evaluation and access to new AD treatments.
Imre Kacskovics - The way toward a vibrant RDI red biotechnology ecosystem
The document outlines a proposed strategy to develop a vibrant red biotechnology ecosystem in Hungary by exploiting research potential and setting up a supportive environment. Key elements include:
1) Mapping the current academic and company portfolio to identify strengths and opportunities.
2) Establishing an umbrella organization to develop a focused research and service portfolio responsive to industry needs, and set up joint infrastructure like incubators.
3) Creating a highly supportive environment for innovative SMEs and large companies through business development support, one-stop shops for industry partnerships, and an entrepreneurial mindset.
The goal is to dynamize the pharmaceutical and biotech sector through excellence, partnerships between industry and universities, and sustainable growth over the long term
Μάκης Παπαταξιάρχης - 6th Clinical Research Conference
Ομιλία: Μάκης Παπαταξιάρχης, Διευθύνων Σύμβουλος Janssen Ελλάδος, Pharmaceutical Companies of Johnson & Johnson, Πρόεδρος του PhRMA Innovation Forum, Πρόεδρος του AmCham Pharmaceutical Committee
Contribution of a world-class regulatory system to the future of the pharmace...
Contribution of a world-class regulatory system to the future of the pharmace...Irish Pharmaceutical Healthcare Association (IPHA)
The document discusses the regulatory environment for medicines in Ireland and Europe. It outlines how the Irish Medicines Board operates within the European system, providing resources to the European Medicines Agency and participating in evaluation, supervision, and inspection. It also discusses the IMB's international involvement, including partnerships with other agencies and participation in initiatives to enhance public health protection globally. Finally, it evaluates factors that contribute to the IMB becoming a "world-class" regulatory body.Blog april2016 companycreation
The document profiles Sabin C. Carme, a transdisciplinary scientist with experience in industry R&D, innovation, and business. It discusses two company cases he has evaluated: PAPE, which involves a drug delivery system using local palladium activation for low toxicity therapy, and opportunities for building strategic advantages. It also includes an analysis of the company's competitive advantage, business model, market forces, strengths, weaknesses and opportunities for further assessment.
Beyond borders
Analysis of drivers that cause restricted access to funding for smaller biotech companies.
A detailed reviewed of the steps
venture capitalists and companies are
taking — models such as fail-fast R&D, asset-centric funding and more.
Proposal of a model that
could radically change R&D by taking a
much more holistic approach to drug
development, sharing information to
learn in real time across the cycle of care
and fundamentally changing how risk
and reward are allocated.
Les biotechnologies de santé en france 2014 vabrégée anglais 26 05 14
The document summarizes a report on the health care biotechnology industry in France. It finds that the sector has grown since 2010 and now includes 457 companies, mainly micro-enterprises. The companies focus on oncology and infectious diseases. While public-private collaborations are common, private funding is lacking, especially for company development beyond the startup stage. The report identifies areas for improvement such as increasing private financing, supporting company growth, strengthening collaborations, and enhancing an international mindset.
Horizon 2020 for SMEs - ttopstart, the Horizon 2020 experts
Horizon 2020 is the foremost non-dilutive funding opportunity for research-intensive industry to finance and accelerate research and innovation activities. The aim of Horizon 2020 is to advance scientific knowledge and discovery, while securing Europe’s growth and global competitiveness through stronger involvement of industry and in particular SMEs.
Havana Atm
The document discusses the Access to Medicine Index, which rates pharmaceutical companies on their efforts to improve access to medicine in developing countries. It summarizes the Index's methodology, which consists of 8 criteria covering areas like pricing, research and development into neglected diseases, and licensing agreements. The Index aims to define the industry's role, increase transparency, and reward good behavior by benchmarking companies. Stakeholders like NGOs, governments, investors, and academics are involved in guiding the Index to help increase access to medicine programs. The first Index publication received global media coverage.
John Soloninka
This document discusses initiatives in Ontario to strengthen its medical technology sector and transition from being a "backwater" to a leader. It outlines several gaps including in procurement, the healthcare system, markets, and policies that have hindered innovation. Recent improvements are noted in ecosystem collaboration through initiatives like the Centre for Imaging Technology Commercialization, Ontario Brain Institute, and EXCITE program for evidence development to support disruptive technologies. The document advocates for continued focus on commercialization and controlled diffusion of innovative technologies to bend the healthcare cost curve.
Innovation in life sciences
This report, commissioned by Dubai Science Park, explores the success of emerging markets in the life sciences industry and identifies strategic lessons for countries seeking to nurture their own life sciences sector.
Similar to IMI Outputs - November 2015 (20)
Pistoia Alliance European Conference 2015 - Ann Martin / IMI
Pistoia Alliance European Conference 2015 - Ann Martin / IMI
Boosting drug development through public private partnerships (Laverty OECD P...
Boosting drug development through public private partnerships (Laverty OECD P...
The Changing Pharma R&D Model, GDDIS Leaders Summit Ted Torphy CSO, Head, Ex...
The Changing Pharma R&D Model, GDDIS Leaders Summit Ted Torphy CSO, Head, Ex...
Earma Annual Conference 23 june 2011 - Magali Poinot (part 1)
Earma Annual Conference 23 june 2011 - Magali Poinot (part 1)
Infection Surveillance Solutions Market PPT: Growth, Outlook, Demand, Keyplay...
Infection Surveillance Solutions Market PPT: Growth, Outlook, Demand, Keyplay...
Graham Hughes - Beta Technology - FP 7 Call Presentation
Graham Hughes - Beta Technology - FP 7 Call Presentation
Real World Outcomes Across the AD (Alzheimer’s disease) Spectrum (ROADS) to B...
Real World Outcomes Across the AD (Alzheimer’s disease) Spectrum (ROADS) to B...
Imre Kacskovics - The way toward a vibrant RDI red biotechnology ecosystem
Imre Kacskovics - The way toward a vibrant RDI red biotechnology ecosystem
Μάκης Παπαταξιάρχης - 6th Clinical Research Conference
Μάκης Παπαταξιάρχης - 6th Clinical Research Conference
Contribution of a world-class regulatory system to the future of the pharmace...
Contribution of a world-class regulatory system to the future of the pharmace...
Les biotechnologies de santé en france 2014 vabrégée anglais 26 05 14
Les biotechnologies de santé en france 2014 vabrégée anglais 26 05 14
Horizon 2020 for SMEs - ttopstart, the Horizon 2020 experts
Horizon 2020 for SMEs - ttopstart, the Horizon 2020 experts
Recently uploaded
Pro-competitive Industrial Policy – OECD – June 2024 OECD discussion
Pro-competitive Industrial Policy – OECD – June 2024 OECD discussionOECD Directorate for Financial and Enterprise Affairs
This presentation by OECD, OECD Secretariat, was made during the discussion “Pro-competitive Industrial Policy” held at the 143rd meeting of the OECD Competition Committee on 12 June 2024. More papers and presentations on the topic can be found at oe.cd/pcip.
This presentation was uploaded with the author’s consent.
Artificial Intelligence, Data and Competition – LIM – June 2024 OECD discussion
Artificial Intelligence, Data and Competition – LIM – June 2024 OECD discussionOECD Directorate for Financial and Enterprise Affairs
This presentation by Yong Lim, Professor of Economic Law at Seoul National University School of Law, was made during the discussion “Artificial Intelligence, Data and Competition” held at the 143rd meeting of the OECD Competition Committee on 12 June 2024. More papers and presentations on the topic can be found at oe.cd/aicomp.
This presentation was uploaded with the author’s consent.
Artificial Intelligence, Data and Competition – OECD – June 2024 OECD discussion
Artificial Intelligence, Data and Competition – OECD – June 2024 OECD discussionOECD Directorate for Financial and Enterprise Affairs
This presentation by OECD, OECD Secretariat, was made during the discussion “Artificial Intelligence, Data and Competition” held at the 143rd meeting of the OECD Competition Committee on 12 June 2024. More papers and presentations on the topic can be found at oe.cd/aicomp.
This presentation was uploaded with the author’s consent.
Artificial Intelligence, Data and Competition – SCHREPEL – June 2024 OECD dis...
Artificial Intelligence, Data and Competition – SCHREPEL – June 2024 OECD dis...OECD Directorate for Financial and Enterprise Affairs
This presentation by Thibault Schrepel, Associate Professor of Law at Vrije Universiteit Amsterdam University, was made during the discussion “Artificial Intelligence, Data and Competition” held at the 143rd meeting of the OECD Competition Committee on 12 June 2024. More papers and presentations on the topic can be found at oe.cd/aicomp.
This presentation was uploaded with the author’s consent.
Competition and Regulation in Professions and Occupations – OECD – June 2024 ...
Competition and Regulation in Professions and Occupations – OECD – June 2024 ...OECD Directorate for Financial and Enterprise Affairs
This presentation by OECD, OECD Secretariat, was made during the discussion “Competition and Regulation in Professions and Occupations” held at the 77th meeting of the OECD Working Party No. 2 on Competition and Regulation on 10 June 2024. More papers and presentations on the topic can be found at oe.cd/crps.
This presentation was uploaded with the author’s consent.
The Intersection between Competition and Data Privacy – CAPEL – June 2024 OEC...
The Intersection between Competition and Data Privacy – CAPEL – June 2024 OEC...OECD Directorate for Financial and Enterprise Affairs
This presentation by Tim Capel, Director of the UK Information Commissioner’s Office Legal Service, was made during the discussion “The Intersection between Competition and Data Privacy” held at the 143rd meeting of the OECD Competition Committee on 13 June 2024. More papers and presentations on the topic can be found at oe.cd/ibcdp.
This presentation was uploaded with the author’s consent.
Proposal: The Ark Project and The BEEP Inc
1.) Introduction
Our Movement is not new; it is the same as it was for Freedom, Justice, and Equality since we were labeled as slaves. However, this movement at its core must entail economics.
2.) Historical Context
This is the same movement because none of the previous movements, such as boycotts, were ever completed. For some, maybe, but for the most part, it’s just a place to keep your stable until you’re ready to assimilate them into your system. The rest of the crabs are left in the world’s worst parts, begging for scraps.
3.) Economic Empowerment
Our Movement aims to show that it is indeed possible for the less fortunate to establish their economic system. Everyone else – Caucasian, Asian, Mexican, Israeli, Jews, etc. – has their systems, and they all set up and usurp money from the less fortunate. So, the less fortunate buy from every one of them, yet none of them buy from the less fortunate. Moreover, the less fortunate really don’t have anything to sell.
4.) Collaboration with Organizations
Our Movement will demonstrate how organizations such as the National Association for the Advancement of Colored People, National Urban League, Black Lives Matter, and others can assist in creating a much more indestructible Black Wall Street.
5.) Vision for the Future
Our Movement will not settle for less than those who came before us and stopped before the rights were equal. The economy, jobs, healthcare, education, housing, incarceration – everything is unfair, and what isn’t is rigged for the less fortunate to fail, as evidenced in society.
6.) Call to Action
Our movement has started and implemented everything needed for the advancement of the economic system. There are positions for only those who understand the importance of this movement, as failure to address it will continue the degradation of the people deemed less fortunate.
No, this isn’t Noah’s Ark, nor am I a Prophet. I’m just a man who wrote a couple of books, created a magnificent website: http://www.thearkproject.llc, and who truly hopes to try and initiate a truly sustainable economic system for deprived people. We may not all have the same beliefs, but if our methods are tried, tested, and proven, we can come together and help others. My website: http://www.thearkproject.llc is very informative and considerably controversial. Please check it out, and if you are afraid, leave immediately; it’s no place for cowards. The last Prophet said: “Whoever among you sees an evil action, then let him change it with his hand [by taking action]; if he cannot, then with his tongue [by speaking out]; and if he cannot, then, with his heart – and that is the weakest of faith.” [Sahih Muslim] If we all, or even some of us, did this, there would be significant change. We are able to witness it on small and grand scales, for example, from climate control to business partnerships. I encourage, invite, and challenge you all to support me by visiting my website.
IEEE CIS Webinar Sustainable futures.pdf
The importance of sustainable and efficient computational practices in artificial intelligence (AI) and deep learning has become increasingly critical. This webinar focuses on the intersection of sustainability and AI, highlighting the significance of energy-efficient deep learning, innovative randomization techniques in neural networks, the potential of reservoir computing, and the cutting-edge realm of neuromorphic computing. This webinar aims to connect theoretical knowledge with practical applications and provide insights into how these innovative approaches can lead to more robust, efficient, and environmentally conscious AI systems.
Webinar Speaker: Prof. Claudio Gallicchio, Assistant Professor, University of Pisa
Claudio Gallicchio is an Assistant Professor at the Department of Computer Science of the University of Pisa, Italy. His research involves merging concepts from Deep Learning, Dynamical Systems, and Randomized Neural Systems, and he has co-authored over 100 scientific publications on the subject. He is the founder of the IEEE CIS Task Force on Reservoir Computing, and the co-founder and chair of the IEEE Task Force on Randomization-based Neural Networks and Learning Systems. He is an associate editor of IEEE Transactions on Neural Networks and Learning Systems (TNNLS).
原版制作贝德福特大学毕业证（bedfordhire毕业证）硕士文凭原版一模一样
原版一模一样【微信：741003700 】【贝德福特大学毕业证（bedfordhire毕业证）硕士文凭】【微信：741003700 】学位证，留信认证（真实可查，永久存档）offer、雅思、外壳等材料/诚信可靠,可直接看成品样本，帮您解决无法毕业带来的各种难题！外壳，原版制作，诚信可靠，可直接看成品样本。行业标杆！精益求精，诚心合作，真诚制作！多年品质 ,按需精细制作，24小时接单,全套进口原装设备。十五年致力于帮助留学生解决难题，包您满意。
本公司拥有海外各大学样板无数，能完美还原海外各大学 Bachelor Diploma degree, Master Degree Diploma
1:1完美还原海外各大学毕业材料上的工艺：水印，阴影底纹，钢印LOGO烫金烫银，LOGO烫金烫银复合重叠。文字图案浮雕、激光镭射、紫外荧光、温感、复印防伪等防伪工艺。材料咨询办理、认证咨询办理请加学历顾问Q/微741003700
留信网认证的作用:
1:该专业认证可证明留学生真实身份
2:同时对留学生所学专业登记给予评定
3:国家专业人才认证中心颁发入库证书
4:这个认证书并且可以归档倒地方
5:凡事获得留信网入网的信息将会逐步更新到个人身份内，将在公安局网内查询个人身份证信息后，同步读取人才网入库信息
6:个人职称评审加20分
7:个人信誉贷款加10分
8:在国家人才网主办的国家网络招聘大会中纳入资料，供国家高端企业选择人才
Pro-competitive Industrial Policy – LANE – June 2024 OECD discussion
Pro-competitive Industrial Policy – LANE – June 2024 OECD discussionOECD Directorate for Financial and Enterprise Affairs
This presentation by Nathaniel Lane, Associate Professor in Economics at Oxford University, was made during the discussion “Pro-competitive Industrial Policy” held at the 143rd meeting of the OECD Competition Committee on 12 June 2024. More papers and presentations on the topic can be found at oe.cd/pcip.
This presentation was uploaded with the author’s consent.
ServiceNow CIS-ITSM Exam Dumps & Questions [2024]
• For a full set of 530+ questions. Go to
https://skillcertpro.com/product/servicenow-cis-itsm-exam-questions/
• SkillCertPro offers detailed explanations to each question which helps to understand the concepts better.
• It is recommended to score above 85% in SkillCertPro exams before attempting a real exam.
• SkillCertPro updates exam questions every 2 weeks.
• You will get life time access and life time free updates
• SkillCertPro assures 100% pass guarantee in first attempt.
The Intersection between Competition and Data Privacy – KEMP – June 2024 OECD...
The Intersection between Competition and Data Privacy – KEMP – June 2024 OECD...OECD Directorate for Financial and Enterprise Affairs
This presentation by Katharine Kemp, Associate Professor at the Faculty of Law & Justice at UNSW Sydney, was made during the discussion “The Intersection between Competition and Data Privacy” held at the 143rd meeting of the OECD Competition Committee on 13 June 2024. More papers and presentations on the topic can be found at oe.cd/ibcdp.
This presentation was uploaded with the author’s consent.
Why Psychological Safety Matters for Software Teams - ACE 2024 - Ben Linders.pdf
Psychological safety in teams is important; team members must feel safe and able to communicate and collaborate effectively to deliver value. It’s also necessary to build long-lasting teams since things will happen and relationships will be strained.
But, how safe is a team? How can we determine if there are any factors that make the team unsafe or have an impact on the team’s culture?
In this mini-workshop, we’ll play games for psychological safety and team culture utilizing a deck of coaching cards, The Psychological Safety Cards. We will learn how to use gamification to gain a better understanding of what’s going on in teams. Individuals share what they have learned from working in teams, what has impacted the team’s safety and culture, and what has led to positive change.
Different game formats will be played in groups in parallel. Examples are an ice-breaker to get people talking about psychological safety, a constellation where people take positions about aspects of psychological safety in their team or organization, and collaborative card games where people work together to create an environment that fosters psychological safety.
Artificial Intelligence, Data and Competition – ČORBA – June 2024 OECD discus...
Artificial Intelligence, Data and Competition – ČORBA – June 2024 OECD discus...OECD Directorate for Financial and Enterprise Affairs
This presentation by Juraj Čorba, Chair of OECD Working Party on Artificial Intelligence Governance (AIGO), was made during the discussion “Artificial Intelligence, Data and Competition” held at the 143rd meeting of the OECD Competition Committee on 12 June 2024. More papers and presentations on the topic can be found at oe.cd/aicomp.
This presentation was uploaded with the author’s consent.
Disaster Management project for holidays homework and other uses
It talks about disaster management in a helful way.
Using-Presentation-Software-to-the-Fullf.pptx
Slides on 7 Commonly Used Presentation Softwares; thier usage and features.
The Intersection between Competition and Data Privacy – OECD – June 2024 OECD...
The Intersection between Competition and Data Privacy – OECD – June 2024 OECD...OECD Directorate for Financial and Enterprise Affairs
This presentation by OECD, OECD Secretariat, was made during the discussion “The Intersection between Competition and Data Privacy” held at the 143rd meeting of the OECD Competition Committee on 13 June 2024. More papers and presentations on the topic can be found at oe.cd/ibcdp.
This presentation was uploaded with the author’s consent.
怎么办理(lincoln学位证书)英国林肯大学毕业证文凭学位证书原版一模一样
原版定制【微信:bwp0011】《(lincoln学位证书)英国林肯大学毕业证文凭学位证书》【微信:bwp0011】成绩单 、雅思、外壳、留信学历认证永久存档查询，采用学校原版纸张、特殊工艺完全按照原版一比一制作（包括：隐形水印，阴影底纹，钢印LOGO烫金烫银，LOGO烫金烫银复合重叠，文字图案浮雕，激光镭射，紫外荧光，温感，复印防伪）行业标杆！精益求精，诚心合作，真诚制作！多年品质 ,按需精细制作，24小时接单,全套进口原装设备，十五年致力于帮助留学生解决难题，业务范围有加拿大、英国、澳洲、韩国、美国、新加坡，新西兰等学历材料，包您满意。
【业务选择办理准则】
一、工作未确定，回国需先给父母、亲戚朋友看下文凭的情况，办理一份就读学校的毕业证【微信bwp0011】文凭即可
二、回国进私企、外企、自己做生意的情况，这些单位是不查询毕业证真伪的，而且国内没有渠道去查询国外文凭的真假，也不需要提供真实教育部认证。鉴于此，办理一份毕业证【微信bwp0011】即可
三、进国企，银行，事业单位，考公务员等等，这些单位是必需要提供真实教育部认证的，办理教育部认证所需资料众多且烦琐，所有材料您都必须提供原件，我们凭借丰富的经验，快捷的绿色通道帮您快速整合材料，让您少走弯路。
留信网认证的作用:
1:该专业认证可证明留学生真实身份
2:同时对留学生所学专业登记给予评定
3:国家专业人才认证中心颁发入库证书
4:这个认证书并且可以归档倒地方
5:凡事获得留信网入网的信息将会逐步更新到个人身份内，将在公安局网内查询个人身份证信息后，同步读取人才网入库信息
6:个人职称评审加20分
7:个人信誉贷款加10分
8:在国家人才网主办的国家网络招聘大会中纳入资料，供国家高端企业选择人才
【关于价格问题（保证一手价格）】
我们所定的价格是非常合理的，而且我们现在做得单子大多数都是代理和回头客户介绍的所以一般现在有新的单子 我给客户的都是第一手的代理价格，因为我想坦诚对待大家 不想跟大家在价格方面浪费时间
对于老客户或者被老客户介绍过来的朋友，我们都会适当给一些优惠。
BRIC_2024_2024-06-06-11:30-haunschild_archival_version.pdf
These are the slides of my presentation at BRIC 2024 about global science overlay maps using OpenAlex.
Carrer goals.pptx and their importance in real life
Career goals serve as a roadmap for individuals, guiding them toward achieving long-term professional aspirations and personal fulfillment. Establishing clear career goals enables professionals to focus their efforts on developing specific skills, gaining relevant experience, and making strategic decisions that align with their desired career trajectory. By setting both short-term and long-term objectives, individuals can systematically track their progress, make necessary adjustments, and stay motivated. Short-term goals often include acquiring new qualifications, mastering particular competencies, or securing a specific role, while long-term goals might encompass reaching executive positions, becoming industry experts, or launching entrepreneurial ventures.
Moreover, having well-defined career goals fosters a sense of purpose and direction, enhancing job satisfaction and overall productivity. It encourages continuous learning and adaptation, as professionals remain attuned to industry trends and evolving job market demands. Career goals also facilitate better time management and resource allocation, as individuals prioritize tasks and opportunities that advance their professional growth. In addition, articulating career goals can aid in networking and mentorship, as it allows individuals to communicate their aspirations clearly to potential mentors, colleagues, and employers, thereby opening doors to valuable guidance and support. Ultimately, career goals are integral to personal and professional development, driving individuals toward sustained success and fulfillment in their chosen fields.
Recently uploaded (20)
Pro-competitive Industrial Policy – OECD – June 2024 OECD discussion
Pro-competitive Industrial Policy – OECD – June 2024 OECD discussion
Artificial Intelligence, Data and Competition – LIM – June 2024 OECD discussion
Artificial Intelligence, Data and Competition – LIM – June 2024 OECD discussion
Artificial Intelligence, Data and Competition – OECD – June 2024 OECD discussion
Artificial Intelligence, Data and Competition – OECD – June 2024 OECD discussion
Artificial Intelligence, Data and Competition – SCHREPEL – June 2024 OECD dis...
Artificial Intelligence, Data and Competition – SCHREPEL – June 2024 OECD dis...
Competition and Regulation in Professions and Occupations – OECD – June 2024 ...
Competition and Regulation in Professions and Occupations – OECD – June 2024 ...
The Intersection between Competition and Data Privacy – CAPEL – June 2024 OEC...
The Intersection between Competition and Data Privacy – CAPEL – June 2024 OEC...
Pro-competitive Industrial Policy – LANE – June 2024 OECD discussion
Pro-competitive Industrial Policy – LANE – June 2024 OECD discussion
The Intersection between Competition and Data Privacy – KEMP – June 2024 OECD...
The Intersection between Competition and Data Privacy – KEMP – June 2024 OECD...
Why Psychological Safety Matters for Software Teams - ACE 2024 - Ben Linders.pdf
Why Psychological Safety Matters for Software Teams - ACE 2024 - Ben Linders.pdf
Artificial Intelligence, Data and Competition – ČORBA – June 2024 OECD discus...
Artificial Intelligence, Data and Competition – ČORBA – June 2024 OECD discus...
Disaster Management project for holidays homework and other uses
Disaster Management project for holidays homework and other uses
The Intersection between Competition and Data Privacy – OECD – June 2024 OECD...
The Intersection between Competition and Data Privacy – OECD – June 2024 OECD...
BRIC_2024_2024-06-06-11:30-haunschild_archival_version.pdf
BRIC_2024_2024-06-06-11:30-haunschild_archival_version.pdf
Carrer goals.pptx and their importance in real life
Carrer goals.pptx and their importance in real life
IMI Outputs - November 2015
- 1. What is €5 billion worth? Magda Gunn, IMI Scientific Project Manager
- 2. Drug discovery is complex
- 3. Focus on unmet needs Non-competitive collaborative research Competitive Calls for proposals Open collaboration in public-private consortia Data sharing, dissemination of results… Industry contribution is in kind A partnership between EU Commission and the European Federation of Pharmaceutical Industries and Association (EFPIA) Key concepts
- 4. Typical IMI project Industry ACADEMIA HOSPITALS PATIENTS’ ORGANISATIONS SMALL AND MEDIUM-SIZED ENTERPRISES REGULATORS Pharma 1 Pharma 2 Pharma 3 Pharma 4 Pharma 5 Pharma 6 Private Investment in kind EU Public Funding cash
- 5. Many stakeholders many expectations
- 6. 2.7 billion REMAINING 17 CALLS FOR PROPOSALS 2.6 billion COMMITTED 68 PROJECTS 0% 5% 10% 15% 20% 25% 30% 35% 40% Relative Effectiveness Drug kinetics Drug delivery Sustainable chemistry Lung diseases Education and Training Vaccines Geriatrics Biologicals Inflamatory disorders Cancer Data Management Stem cells Drug safety Metabolic disorders Brain disorders Drug Discovery Infectious diseases
- 7. Performance monitoring framework Scientific output Impact on drug development Impact on regulatory framework Business opportunities and sustainability Socio-economic impact Information, communication and dissemination
- 9. 2010 2011 2012 2013 2014 1134 publications by Dec 2014 427376224 24% HIGHLY CITED 1134 PUBLICATIONS 2.19 CITATION IMPACT 9359 CITATIONS IMI scientific output
- 10. Benchmarking 0 0.5 1 1.5 2 2.5 ICMR World EU-28 C-Path CSIRO GCGH WT MRC FNIH IMI Citation impact IMI vs. comparators 0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 Genetics & Heredity Psychiatry Clinical Neurology Neurosciences Rheumatology Biochemistry & Molecular… Immunology Pharmacology & Pharmacy Toxicology Endocrinology & Metabolism IMI vs. EU in various research fields IMI papers EU papers
- 11. Collaboration delivers excellence INTERNATIONAL collaboration 50% of IMI publications Collaboration BETWEEN SECTORS 61% of IMI publications collaboration BETWEEN INSTITUTIONS 75% of IMI publications 0 1 2 3 Cross-institution Cross-sector International Citation impact Collaborative Non-collaborative Data & analysis:Thomson Reuters (Custom Analytics & Engineered Solutions)
- 12. Tracking collaborations across EU Co-authorship between IMI-supported researchers Calls 1-4 Pre IMI funding award Post IMI funding award Data & analysis:Thomson Reuters (Custom Analytics & Engineered Solutions)
- 14. Securing regulatory relevance New standards and best practices derived from IMI projects Number of scientific advice and qualified opinions initiated by the IMI projects at the EMA and FDA Number of regulatory guidelines derived from IMI projects
- 16. IMI project patenting trends 20 patent applications 3.2 patents per €10 million of costs accepted by IMI
- 17. Business relevant outputs (n=50) New Projects Companies & joint ventures Foundations & non-profits Spin-offs breakdown
- 18. Job creation as a result of IMI projects 2 272 direct jobs created 13 000 indirect jobs* * https://researchcouncil.files.wordpress.com/2013/08/walifescienceseconimpactstudy.pdf
- 20. SMEs receive 18% of IMI funding 15% of IMI participants are SMEs Promoting SME participation Thanks to IMI the company went from 6 to 50 employees. Now they are ready to further expand. “1st product released to the market in 2013 – IMI was instrumental in validation of the first cell line product, 2nd product release planned this year, 3rd diagnostic product in development. In preparation: a new patent filing to protect technologies for the creation of third generation human beta cell lines.